title: High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.
abstract: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. mskaruturi@mdanderson.org
authors.forename: Meghan
authors.initials: M
authors.lastname: Karuturi
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
authors.forename: Michelle
authors.initials: M
authors.lastname: Fanale
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: Amin M
authors.initials: AM
authors.lastname: Alousi
authors.forename: Marcos J
authors.initials: MJ
authors.lastname: de Lima
authors.forename: Muzaffar H
authors.initials: MH
authors.lastname: Qazilbash
authors.forename: Partow
authors.initials: P
authors.lastname: Kebriaei
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
authors.forename: Issa
authors.initials: I
authors.lastname: Khouri
authors.forename: Borje S
authors.initials: BS
authors.lastname: Andersson
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Paolo
authors.initials: P
authors.lastname: Anderlini
authors.forename: Uday
authors.initials: U
authors.lastname: Popat
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents